The five-year analysis of the TRANSFORM trial [82], which is one the largest cohort of men with oligometastatic prostate cancer (PCa) treated with SBRT-based metastatic-directed therapy (MDT) with 76.4% patients staging with PSMA-PET/CT. The gene discussed is FOLH1; the disease is posterior cortical atrophy.